Fundraising Fox

Xylocor

Delaware corporation · 5 known investors

xylocor.com ↗

XyloCor Therapeutics develops gene therapies for advanced coronary artery disease and cardiac damage. The company's lead program, XC001, targets refractory angina in patients with limited treatment options.

BiotechHealthtechMedical Devices

Founders & leadership

RC
Ronald CrystalCo-founder
TRTodd Rosengart
Todd RosengartCo-founder
JT
John TuckerPresident and Chief Executive Officer
GB
Glenn BatchelderDirector
JC
James CohenDirector
AG
Albert GianchettiExecutive Officer, Director

Investors · 5

Lumira Ventures✓ verifiedToronto · $1M – $10M
Fountain Healthcare Partners✓ verifiedDublin · $10.8M – $16.2M
Jeito CapitalParis
Longwood FundBoston
Sofinnova VenturesMenlo Park · $100K – $15M

Reported raises · per SEC filings

Form D private placements
▶$4MraisedJan 2021 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Fouad Azzam, Ph.D.Director
  • Aidan KingDirector
  • Michael F. Powell, Ph.D.Director
  • Todd K. Rosengart, M.D.Director
  • Glenn BatchelderDirector
  • Albert GianchettiExecutive Officer, Director
Amount sold
$4M
First sale
Jan 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$16.8MraisedOct 2018 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Todd RosengartDirector
  • Glenn BatchelderDirector
  • Albert GianchettiExecutive Officer, Director
  • James CohenDirector
Offering amount
$16.8M
Amount sold
$16.8M
First sale
Oct 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$200KraisedJul 2018 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Glenn BatchelderDirector
  • James CohenDirector
  • Todd RosengartDirector
  • Albert GianchettiExecutive Officer, Director
Offering amount
$200K
Amount sold
$200K
First sale
Jul 2018
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$60KraisedMar 2018 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • James CohenDirector
  • Glenn BatchelderDirector
  • Albert GianchettiExecutive Officer, Director
  • Todd RosengartDirector
Offering amount
$150K
Amount sold
$60K
First sale
Mar 2018
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$100KraisedDec 2017 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Todd RosengartDirector
  • Glenn BatchelderDirector
  • James CohenDirector
  • Albert GianchettiExecutive Officer, Director
Offering amount
$100K
Amount sold
$100K
First sale
Nov 2017
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$250KraisedNov 2016 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Glenn BatchelderDirector
  • James CohenDirector
  • Albert GianchettiExecutive Officer, Director
Offering amount
$1M
Amount sold
$250K
First sale
Nov 2016
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news